pharmatimesApril 02, 2020
Tag: AstraZeneca , Movantik , RedHill Biopharma
AstraZeneca has completed its deal to sublicense global rights to Movantik (naloxegol), (excluding Europe, Canada and Israel) to RedHill Biopharma.
In 2015, AZ entered into a co-commercialisation agreement with Daiichi Sankyo for the drug in the US, which has now been transferred to RedHill, for $52.5 million.
AZ, which will continue to manufacture and supply Movantik to RedHill druing the transition period, also stands to receive a further non-contingent payment of $15 million in 2021.
In 2019, Movantik generated sales of $96 million in the US, where it is marketed for the treatment of OIC (opioid-induced constipation) in adult patients with chronic non-cancer pain.
In 2016, AZ divested EU rights to the once-daily oral peripherally acting mu-opioid receptor antagonist to ProStrakan Group (now KKI) and the rights in Canada and Israel to Knight Therapeutics.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: